← Back to Screener
XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB)
Price$2.06
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-49.30%
Price vs S&P 500 (4W)-26.08%
VGM Score29.49
All Metrics
Price vs S&P 500 (YTD)-36.13%
10-Day Avg Trading Volume2.59M
3-Month Avg Trading Volume4.13M
52-Week High$11.80
26-Week Price Return-41.38%
13-Week Price Return-19.05%
3-Month Return Std Dev127.89%
Year-to-Date Return-29.17%
5-Day Price Return-5.56%
Month-to-Date Return-5.56%
Price vs S&P 500 (13W)-27.30%
Beta0.76x
52-Week Low$1.70
mGradeD
vgmGradeD
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
XTLBXTL Biopharmaceuticals Ltd. American Depositary Shares | — | — | D | $2.06 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
XTL Biopharmaceuticals develops therapeutics for unmet medical needs in autoimmune and oncology indications. Its lead candidate, hCDR1, is a synthetic peptide in Phase II development for systemic lupus erythematosus and Sjögren's syndrome. The company is also advancing rHuEPO, a recombinant human erythropoietin, to extend survival in multiple myeloma patients.